SCHEMBL2684375

SCHEMBL2684375

O=C(O)Cc1ccsc1Br

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 1/20 0.44
SLC6A3 Q01959 1/20 0.44
AKR1B1 P15121 3/20 0.42
FFAR4 Q5NUL3 1/20 0.42
KMT2A Q03164 3/20 0.41
TP53 P04637 1/20 0.41
ALOX15 P16050 1/20 0.41
MAPK1 P28482 1/20 0.41
KEAP1 Q14145 1/20 0.38
NFE2L2 Q16236 1/20 0.38
TDP1 Q9NUW8 1/20 0.37
PTGDR2 Q9Y5Y4 2/20 0.35
KDM4E B2RXH2 1/20 0.35
CYP1A2 P05177 1/20 0.35
MAPT P10636 1/20 0.35
ABCB11 O95342 1/20 0.35
LMNA P02545 1/20 0.35
PTGS1 P23219 1/20 0.35
ADORA1 P30542 1/20 0.35
PTGS2 P35354 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28511312 0.85 SLC6A4 (0.41) SLC6A4SLC6A3FFAR4KMT2ATP53
SCHEMBL23330448 0.82 SLC6A4 (0.39) SLC6A4SLC6A3FFAR4KMT2ATP53
SCHEMBL31125031 0.80 FFAR4 (0.46) SLC6A4SLC6A3FFAR4KEAP1TDP1
SCHEMBL2684136 0.77 KMT2A (0.41) SLC6A4SLC6A3KMT2ATP53ALOX15
SCHEMBL10424599 0.77 AKR1B1 (0.43) AKR1B1KMT2ATP53ALOX15MAPK1
SCHEMBL27267321 0.77 AKR1B1 (0.48) AKR1B1KMT2ATP53ALOX15MAPK1
SCHEMBL3532102 0.75 KEAP1 (0.45) AKR1B1KMT2ATP53ALOX15MAPK1
SCHEMBL2779682 0.75 PTPN2 (0.43) AKR1B1KMT2ATP53ALOX15MAPK1
SCHEMBL11420003 0.75 AKR1B1 (0.42) AKR1B1KMT2ATP53ALOX15MAPK1
SCHEMBL1136796 0.75 AKR1B1 (0.42) AKR1B1KMT2ATP53ALOX15MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2875010-B1 THIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES METABRAIN RES (FR) 2016-08-31 EP disclosed
CN-102812016-B Organic electronic devices and polymers including photovoltaic cells and diketone-based polymers SOLVAY USA INC. (US) 2015-12-09 CN disclosed
EP-2875010-A1 THIOPHENE DERIVATIVES USED IN THE TREATMENT OF DIABETES Metabrain Research (FR) 2015-05-27 EP disclosed
WO-2014013181-A1 THIOPHENE DERIVATIVES USED IN THE TREATMENT OF DIABETES METABRAIN RESEARCH (FR) 2014-01-23 WO disclosed
US-8492428-B2 Small-molecule botulinum toxin inhibitors MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2013-07-23 US disclosed
US-8404728-B2 Small-molecule botulinum toxin inhibitors MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2013-03-26 US disclosed
CN-102812016-A Organic electronic devices and polymers including photovoltaic cells and diketone-based polymers PLEXTRONICS INC 2012-12-05 CN disclosed
US-20120114696-A1 SMALL-MOLECULE BOTULINUM TOXIN INHIBITORS US ARMY, SECRETARY OF THE ARMY 2012-05-10 US disclosed
US-20100260778-A1 SMALL-MOLECULE BOTULINUM TOXIN INHIBITORS MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH 2010-10-14 US disclosed
EP-1556376-B1 LARGE CONDUCTANCE CALCIUM-ACTIVATED K CHANNEL OPENER MITSUBISHI TANABE PHARMA CORP (JP) 2008-07-16 EP disclosed
US-20050171132-A1 Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists XIN ZHILI (US) 2005-08-04 US disclosed
WO-2005030734-A1 DIAMINOPYRIMIDINE DERIVATIVES AS SELECTIVE GROWTH HORMONE SECRECTGOGUE RECEPTOR (GHS-R) ANTAGONISTS ABBOTT LABORATORIES (US) 2005-04-07 WO disclosed
EP-1077701-A4 ANTI-VIRAL COMPOUNDS LILLY CO ELI (US) 2002-03-20 EP disclosed
EP-1077701-A1 ANTI-VIRAL COMPOUNDS ELI LILLY AND COMPANY (US) 2001-02-28 EP disclosed
WO-1999059587-A1 ANTI-VIRAL COMPOUNDS ELI LILLY AND COMPANY (US) 1999-11-25 WO disclosed
US-5843947-A N-pyridyl carboxamides and derivatives ADIR ET COMPAGNIE (FR) 1998-12-01 US disclosed
US-5712294-A N-pyridyl carboxamides and derivatives ADIR ET COMPAGNIE (FR) 1998-01-27 US disclosed
US-4329363-A Substituted mercapto acid amides and their use MERCK & CO., INC. (US) 1982-05-11 US disclosed
US-4216160-A IMMUNOREGULANTS FOR CORRECTING AN INBALANCE OF IMMUNE HOMEOSTASIS MERCK & CO., INC. (US) 1980-08-05 US disclosed
EP-0001989-A1 Substituted mercapto acid amides, process for their preparation, pharmaceutical composition containing same and their use MERCK & CO. INC. (US) 1979-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120114696-A1 SMALL-MOLECULE BOTULINUM TOXIN INHIBITORS BTD, BCHE, ACHE SLC6A4 871/4885SLC6A3 584/4885AKR1B1 4716/4885
US-20050171132-A1 Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists GHSR, GIPR, GPR119 SLC6A4 1483/4885SLC6A3 437/4885AKR1B1 804/4885
US-20100260778-A1 SMALL-MOLECULE BOTULINUM TOXIN INHIBITORS BTD, RAC2, BTN3A1 SLC6A4 2081/4885SLC6A3 2089/4885AKR1B1 4459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.